2008 Clinical Practice Guidelines - Canadian Diabetes Association
2008 Clinical Practice Guidelines - Canadian Diabetes Association
2008 Clinical Practice Guidelines - Canadian Diabetes Association
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
vascular endothelial growth factor aptamer, for diabetic macular<br />
edema. Ophthalmology. 2005;112:1747-1757.<br />
66. Chun DW, Heier JS,Topping TM, et al. A pilot study of multiple<br />
intravitreal injections of ranibizumab in patients with center-involving<br />
clinically significant diabetic macular edema.<br />
Ophthalmology. 2006;113:1706-1712.<br />
67. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal<br />
neovascularization after pegaptanib (Macugen) therapy in diabetic<br />
individuals. Ophthalmology. 2006;113:23-28.<br />
68. Grover D, Li J, Chong CW. Intravitreal steroid for macular edema<br />
in diabetes. Cochrane Database Syst Rev. <strong>2008</strong>;(1):CD005656.<br />
69. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone<br />
compared with macular laser grid photocoagulation for the<br />
treatment of cystoid macular edema. Am J Ophthalmol. 2005;<br />
140;695-702.<br />
70. Jonas JB, Kampperter BA, Harder B, et al. Intravitreal triamcinolone<br />
acetonide for diabetic macular edema: a prospective,<br />
randomized study. J Ocul Pharmacol Ther. 2006;22:200-207.<br />
71. Sutter FK, Simpson JM, Gilles MC. Intravitreal triamcinolone<br />
for diabetic macular edema that persists after laser treatment:<br />
three-month efficacy and safety results of a prospective, randomized,<br />
double-masked, placebo-controlled clinical trial.<br />
Ophthalmology. 2004;111:2044-2049.<br />
72. Pearson PA, Baker CW, Eliott D, et al. Fluocinolone acetonide<br />
intravitreal implant for diabetic macular edema: 2 year results.<br />
<strong>Association</strong> for Research in Vision and Ophthalmology Annual<br />
Meeting; April 25-29, 2004; Fort Lauderdale, FL.<br />
73. Pearson PA, Levy B, Comstock T. Fluocinolone acetonide<br />
Implant Study Group. Fluocinolone acetonide intravitreal<br />
implant to treat diabetic macular edema: 3-year results of a<br />
multi-center clinical trial. <strong>Association</strong> for Research in Vision<br />
and Ophthalmology Annual Meeting;April 30 to May 4, 2006;<br />
Fort Lauderdale, FL.<br />
74. Kuppermann BD, Blumenkranz MS, Haller JA, et al.<br />
Randomized controlled study of an intravitreous dexamethasone<br />
drug delivery system in patients with persistent macular<br />
edema. Arch Ophthalmol. 2007;125:309-317.<br />
75. Sjølie AK, Porta M, Parving HH, et al; The DIRECT<br />
Programme Study Group. The DIabetic REtinopathy<br />
Candesartan Trials (DIRECT) Programme: baseline characteristics.<br />
J Renin Angiotensin Aldosterone Syst. 2005;6:25-32.<br />
76. ADVANCE Management Committee. Study rational and design<br />
of ADVANCE: Action in <strong>Diabetes</strong> and Vascular Disease –<br />
preterax and diamicron MR controlled evaluation. Diabetologia.<br />
2001;44:1118-1120.<br />
77. Klein R, Zinman B, Gardiner R, et al.The relationship of diabetic<br />
retinopathy to preclinical diabetic glomerulopathy<br />
lesions in type 1 diabetic patients: the Renin-Angiotensin<br />
System Study. <strong>Diabetes</strong>. 2005;54:527-533.<br />
78. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril<br />
on progression of retinopathy in normotensive people<br />
with type 1 diabetes.The EUCLID Study Group. EURODIAB<br />
Controlled Trial of Lisinopril in Insulin-Dependent <strong>Diabetes</strong><br />
Mellitus. Lancet. 1998;351:28-31.<br />
79. UK Prospective <strong>Diabetes</strong> Study (UKPDS) Group. Effects of<br />
intensive blood-glucose control with metformin on complications<br />
in overweight patients with type 2 diabetes (UKPDS 34).<br />
Lancet. 1998;352:854-865.<br />
S139<br />
COMPLICATIONS AND COMORBIDITIES
Change language